Q-omics provides the consensus-scored SOD3 profile across patient tissues and cancer cell-line models. SOD3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, SOD3 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, SOD3 protein abundance shows 27,974 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight LUSC, KICH, and UCEC as cancer lineages where SOD3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SOD3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SOD3 survival associations across molecular data types. SOD3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SOD3 RNA expression–survival associations across cancer types. High SOD3 expression shows unfavorable associations in LUSC and LGG, but favorable associations in COAD, SKCM, PAAD and LUAD. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for SOD3 RNA expression.
This table summarizes SOD3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 10. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SOD3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SOD3 shows lower tumor expression in KICH, BLCA, THCA, KIRC, LUSC and BRCA. The KICH box plot shows higher SOD3 RNA expression in normal versus tumor tissue (log2 FC = −5.757, t-test p < 0.001).
This table shows molecular features associated with SOD3 in patient tissues and cancer cell lines. In patient samples, SOD3 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, SOD3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BONE and CNS.
